Prognostic significance of C-reactive protein in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Shun KanekoYasuhiro AsahinaMiyako MurakawaShunsuke UeyamaChiaki MaeyashikiHideki WatanabeAkiko Kusano-KitazumeAyako SatoKozue UchidateTakehito AsakawaSho WatanabeYasuhiro IizukaIsamu ShibataShinya OookaYuko KarakamaTakashi FujiiTaro WatabeKeiichi AkahoshiMinoru TanabeKento InadaTomohiro MochidaKeiya WatakabeTaro ShimizuJun TsuchiyaMasato MiyoshiFukiko Kitahata-KawaiSayuri NittaMina NakagawaSei KakinumaRyuichi Okamotonull null

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2024)

CRP was a significant biomarker in patients treated with ATZ + BEV for HCC. Elevated CRP levels may indicate aggressive cancer progression and potential resistance to ATZ + BEV therapy.

Keyphrases

papillary thyroid
squamous cell
locally advanced
liver metastases
metastatic colorectal cancer
stem cells
human health
childhood cancer
newly diagnosed
cell therapy